Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.

D'Alterio C, Buoncervello M, Ieranò C, Napolitano M, Portella L, Rea G, Barbieri A, Luciano A, Scognamiglio G, Tatangelo F, Anniciello AM, Monaco M, Cavalcanti E, Maiolino P, Romagnoli G, Arra C, Botti G, Gabriele L, Scala S.

J Exp Clin Cancer Res. 2019 Oct 28;38(1):432. doi: 10.1186/s13046-019-1420-8.

2.

A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function.

Lam MT, Coppola S, Krumbach OHF, Prencipe G, Insalaco A, Cifaldi C, Brigida I, Zara E, Scala S, Di Cesare S, Martinelli S, Di Rocco M, Pascarella A, Niceta M, Pantaleoni F, Ciolfi A, Netter P, Carisey AF, Diehl M, Akbarzadeh M, Conti F, Merli P, Pastore A, Levi Mortera S, Camerini S, Farina L, Buchholzer M, Pannone L, Cao TN, Coban-Akdemir ZH, Jhangiani SN, Muzny DM, Gibbs RA, Basso-Ricci L, Chiriaco M, Dvorsky R, Putignani L, Carsetti R, Janning P, Stray-Pedersen A, Erichsen HC, Horne A, Bryceson YT, Torralba-Raga L, Ramme K, Rosti V, Bracaglia C, Messia V, Palma P, Finocchi A, Locatelli F, Chinn IK, Lupski JR, Mace EM, Cancrini C, Aiuti A, Ahmadian MR, Orange JS, De Benedetti F, Tartaglia M.

J Exp Med. 2019 Oct 10. pii: jem.20190147. doi: 10.1084/jem.20190147. [Epub ahead of print]

PMID:
31601675
3.

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.

Ottaiano A, Scala S, Normanno N, Napolitano M, Capozzi M, Rachiglio AM, Roma C, Trotta AM, D'Alterio C, Portella L, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Tafuto S, Avallone A, De Stefano A, Tamburini M, Picone C, Petrillo A, Izzo F, Palaia R, Albino V, Amore A, Belli A, Pace U, Di Marzo M, Chiodini P, Botti G, De Feo G, Delrio P, Nasti G.

BMC Cancer. 2019 Sep 9;19(1):899. doi: 10.1186/s12885-019-6109-z.

4.

Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion.

D'Alterio C, Scala S, Sozzi G, Roz L, Bertolini G.

Semin Cancer Biol. 2019 Aug 24. pii: S1044-579X(19)30174-9. doi: 10.1016/j.semcancer.2019.08.019. [Epub ahead of print] Review.

5.

Ionizing radiation effects on the tumor microenvironment.

Portella L, Scala S.

Semin Oncol. 2019 Jun;46(3):254-260. doi: 10.1053/j.seminoncol.2019.07.003. Epub 2019 Jul 30. Review.

PMID:
31383368
6.

CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.

Ieranò C, D'Alterio C, Giarra S, Napolitano M, Rea G, Portella L, Santagata A, Trotta AM, Barbieri A, Campani V, Luciano A, Arra C, Anniciello AM, Botti G, Mayol L, De Rosa G, Pacelli R, Scala S.

Cell Death Dis. 2019 Jul 22;10(8):562. doi: 10.1038/s41419-019-1796-6.

7.

In vivo dynamics of human hematopoietic stem cells: novel concepts and future directions.

Scala S, Aiuti A.

Blood Adv. 2019 Jun 25;3(12):1916-1924. doi: 10.1182/bloodadvances.2019000039. Review.

8.

Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment.

Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S.

Cancer Manag Res. 2019 May 1;11:3847-3860. doi: 10.2147/CMAR.S188316. eCollection 2019. Review.

9.

Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.

Ferrua F, Cicalese MP, Galimberti S, Giannelli S, Dionisio F, Barzaghi F, Migliavacca M, Bernardo ME, Calbi V, Assanelli AA, Facchini M, Fossati C, Albertazzi E, Scaramuzza S, Brigida I, Scala S, Basso-Ricci L, Pajno R, Casiraghi M, Canarutto D, Salerio FA, Albert MH, Bartoli A, Wolf HM, Fiori R, Silvani P, Gattillo S, Villa A, Biasco L, Dott C, Culme-Seymour EJ, van Rossem K, Atkinson G, Valsecchi MG, Roncarolo MG, Ciceri F, Naldini L, Aiuti A.

Lancet Haematol. 2019 May;6(5):e239-e253. doi: 10.1016/S2352-3026(19)30021-3. Epub 2019 Apr 10.

10.

Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors.

Smart K, Cox SML, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1179-1183. doi: 10.1007/s00259-018-4252-4. Epub 2019 Jan 9.

11.

Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans.

Smart K, Cox SML, Kostikov A, Shalai A, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1175-1178. doi: 10.1007/s00259-018-4237-3. Epub 2019 Jan 3.

PMID:
30607444
12.

Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.

Trotta AM, Santagata S, Zanotta S, D'Alterio C, Napolitano M, Rea G, Camerlingo R, Esposito F, Lamantia E, Anniciello A, Botti G, Longo N, Botti G, Pignata S, Perdonà S, Scala S.

J Exp Clin Cancer Res. 2018 Dec 4;37(1):297. doi: 10.1186/s13046-018-0952-7.

13.

Neurocognitive and Hormonal Correlates of Voluntary Weight Loss in Humans.

Neseliler S, Hu W, Larcher K, Zacchia M, Dadar M, Scala SG, Lamarche M, Zeighami Y, Stotland SC, Larocque M, Marliss EB, Dagher A.

Cell Metab. 2019 Jan 8;29(1):39-49.e4. doi: 10.1016/j.cmet.2018.09.024. Epub 2018 Oct 18.

PMID:
30344017
14.

Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans.

Scala S, Basso-Ricci L, Dionisio F, Pellin D, Giannelli S, Salerio FA, Leonardelli L, Cicalese MP, Ferrua F, Aiuti A, Biasco L.

Nat Med. 2018 Nov;24(11):1683-1690. doi: 10.1038/s41591-018-0195-3. Epub 2018 Oct 1.

PMID:
30275570
15.

Erratum to "Mitochondrial Serine Protease HTRA2 p.G399S in a Female with Di George Syndrome and Parkinson's Disease".

Gambardella S, Ferese R, Scala S, Carboni S, Biagioni F, Giardina E, Zampatti S, Modugno N, Fabbiano F, Fornai F, Centonze D, Ruggieri S.

Parkinsons Dis. 2018 Sep 9;2018:5956437. doi: 10.1155/2018/5956437. eCollection 2018.

16.

T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency.

Brigida I, Zoccolillo M, Cicalese MP, Pfajfer L, Barzaghi F, Scala S, Oleaga-Quintas C, Álvarez-Álvarez JA, Sereni L, Giannelli S, Sartirana C, Dionisio F, Pavesi L, Benavides-Nieto M, Basso-Ricci L, Capasso P, Mazzi B, Rosain J, Marcus N, Lee YN, Somech R, Degano M, Raiola G, Caorsi R, Picco P, Moncada Velez M, Khourieh J, Arias AA, Bousfiha A, Issekutz T, Issekutz A, Boisson B, Dobbs K, Villa A, Lombardo A, Neven B, Moshous D, Casanova JL, Franco JL, Notarangelo LD, Scielzo C, Volpi S, Dupré L, Bustamante J, Gattorno M, Aiuti A.

Blood. 2018 Nov 29;132(22):2362-2374. doi: 10.1182/blood-2018-07-863431. Epub 2018 Sep 25.

PMID:
30254128
17.

Heterozygous PLA2G6 Mutation Leads to Iron Accumulation Within Basal Ganglia and Parkinson's Disease.

Ferese R, Scala S, Biagioni F, Giardina E, Zampatti S, Modugno N, Colonnese C, Storto M, Fornai F, Novelli G, Ruggieri S, Gambardella S.

Front Neurol. 2018 Jul 10;9:536. doi: 10.3389/fneur.2018.00536. eCollection 2018.

18.

Mitochondrial Serine Protease HTRA2 p.G399S in a Female with Di George Syndrome and Parkinson's Disease.

Gambardella S, Ferese R, Scala S, Carboni S, Biagioni F, Giardina E, Zampatti S, Modugno N, Fabbiano F, Fornai F, Centonze D, Ruggieri S.

Parkinsons Dis. 2018 Jun 21;2018:5651435. doi: 10.1155/2018/5651435. eCollection 2018. Erratum in: Parkinsons Dis. 2018 Sep 9;2018:5956437. Emiliano, Giardina [corrected to Giardina, Emiliano].

19.

A prospective study of benign fasciculation syndrome and anxiety.

Filippakis A, Jara J, Ventura N, Scala S, Scopa C, Ruthazer R, Karakis I, Srinivasan J, Russell JA, Ho DT.

Muscle Nerve. 2018 Dec;58(6):852-854. doi: 10.1002/mus.26193. Epub 2018 Sep 11.

PMID:
30028521
20.

Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

Consolaro A, Bovis F, Pistorio A, Cimaz R, De Benedetti F, Miniaci A, Corona F, Gerloni V, Martino S, Pastore S, Barone P, Pieropan S, Cortis E, Podda RA, Gallizzi R, Civino A, La Torre F, Rigante D, Consolini R, Maggio MC, Magni-Manzoni S, Perfetti F, Filocamo G, Toppino C, Licciardi F, Garrone M, Scala S, Patrone E, Tonelli M, Tani D, Ravelli A, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Rheumatol Int. 2018 Jul;38(7):1311-1313. doi: 10.1007/s00296-018-4042-0.

21.

Engineering of thermoresponsive gels as a fake metastatic niche.

Giarra S, Ierano C, Biondi M, Napolitano M, Campani V, Pacelli R, Scala S, De Rosa G, Mayol L.

Carbohydr Polym. 2018 Jul 1;191:112-118. doi: 10.1016/j.carbpol.2018.03.016. Epub 2018 Mar 10.

PMID:
29661298
22.

Cationic nucleopeptides as novel non-covalent carriers for the delivery of peptide nucleic acid (PNA) and RNA oligomers.

Tomassi S, Ieranò C, Mercurio ME, Nigro E, Daniele A, Russo R, Chambery A, Baglivo I, Pedone PV, Rea G, Napolitano M, Scala S, Cosconati S, Marinelli L, Novellino E, Messere A, Di Maro S.

Bioorg Med Chem. 2018 May 15;26(9):2539-2550. doi: 10.1016/j.bmc.2018.04.017. Epub 2018 Apr 7.

PMID:
29656988
23.

The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

Consolaro A, Bovis F, Pistorio A, Cimaz R, De Benedetti F, Miniaci A, Corona F, Gerloni V, Martino S, Pastore S, Barone P, Pieropan S, Cortis E, Podda RA, Gallizzi R, Civino A, Torre F, Rigante D, Consolini R, Maggio MC, Magni-Manzoni S, Perfetti F, Filocamo G, Toppino C, Licciardi F, Garrone M, Scala S, Patrone E, Tonelli M, Tani D, Ravelli A, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Rheumatol Int. 2018 Apr;38(Suppl 1):251-258. doi: 10.1007/s00296-018-3960-1. Epub 2018 Apr 7. Erratum in: Rheumatol Int. 2018 May 21;:.

24.

Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology.

Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone E, Rinaldi M, Villa L, Martini A, Ravelli A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Rheumatol Int. 2018 Apr;38(Suppl 1):5-17. doi: 10.1007/s00296-018-3944-1. Epub 2018 Apr 7. Review.

25.

Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells.

Brancaccio D, Diana D, Di Maro S, Di Leva FS, Tomassi S, Fattorusso R, Russo L, Scala S, Trotta AM, Portella L, Novellino E, Marinelli L, Carotenuto A.

J Med Chem. 2018 Apr 12;61(7):2910-2923. doi: 10.1021/acs.jmedchem.7b01830. Epub 2018 Mar 19.

PMID:
29522685
26.

Retraction for Melillo et al., "Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation".

Melillo RM, Pierantoni GM, Scala S, Battista S, Fedele M, Stella A, De Biasio MC, Chiappetta G, Fidanza V, Condorelli G, Santoro M, Croce CM, Viglietto G, Fusco A.

Mol Cell Biol. 2018 Feb 27;38(6). pii: e00660-17. doi: 10.1128/MCB.00660-17. Print 2018 Mar 15. No abstract available.

27.

Patient's experiences with the care for juvenile idiopathic arthritis across Europe.

van Dijkhuizen EHP, Egert T, Egert Y, Costello W, Schoemaker C, Fernhout M, Kepic M, Martini A, Scala S, Rotstein-Grein I, Vastert SJ, Wulffraat NM.

Pediatr Rheumatol Online J. 2018 Feb 8;16(1):10. doi: 10.1186/s12969-018-0226-0.

28.

Structural modeling of altered CLCN1 conformation following a novel mutation in a patient affected by autosomal dominant myotonia congenita (Thomsen disease).

Ferese R, Albano V, Falconi M, Iacovelli F, Campopiano R, Scala S, Griguoli AM, Gaglione A, Giardina E, Zampatti S, Storto M, Fornai F, D'Alessio C, Novelli G, Gambardella S.

Arch Ital Biol. 2017 Dec 1;155(4):118-130. doi: 10.12871/000398292017410. No abstract available.

PMID:
29405036
29.

Predictive immune biomarkers: an unattainable chimera?

Trotta AM, Pacelli R, Scala S.

Cell Mol Immunol. 2018 Aug;15(8):740-742. doi: 10.1038/cmi.2017.162. Epub 2018 Feb 5. No abstract available.

30.

Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy.

Ottaiano A, Napolitano M, Capozzi M, Tafuto S, Avallone A, Scala S.

World J Clin Cases. 2017 Nov 16;5(11):390-396. doi: 10.12998/wjcc.v5.i11.390.

31.

Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.

Di Maro S, Di Leva FS, Trotta AM, Brancaccio D, Portella L, Aurilio M, Tomassi S, Messere A, Sementa D, Lastoria S, Carotenuto A, Novellino E, Scala S, Marinelli L.

J Med Chem. 2017 Dec 14;60(23):9641-9652. doi: 10.1021/acs.jmedchem.7b01062. Epub 2017 Nov 20.

PMID:
29125295
32.

Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer.

Santagata S, Napolitano M, D'Alterio C, Desicato S, Maro SD, Marinelli L, Fragale A, Buoncervello M, Persico F, Gabriele L, Novellino E, Longo N, Pignata S, Perdonà S, Scala S.

Oncotarget. 2017 Aug 19;8(44):77110-77120. doi: 10.18632/oncotarget.20363. eCollection 2017 Sep 29.

33.

PCR-based approach for qualitative molecular analysis of six neurotropic pathogens.

Ferese R, Scorzolini L, Campopiano R, Albano V, Griguoli AM, Giardina E, Scala S, Ryskalin L, D'Alessio C, Zampatti S, Fantozzi R, Storto M, Fornai F, Gambardella S.

Acta Virol. 2017;61(3):273-279. doi: 10.4149/av_2017_305.

PMID:
28854791
34.

Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis.

Aversa I, Zolea F, Ieranò C, Bulotta S, Trotta AM, Faniello MC, De Marco C, Malanga D, Biamonte F, Viglietto G, Cuda G, Scala S, Costanzo F.

J Exp Clin Cancer Res. 2017 Aug 3;36(1):104. doi: 10.1186/s13046-017-0571-8.

35.

Multiparametric Whole Blood Dissection: A one-shot comprehensive picture of the human hematopoietic system.

Basso-Ricci L, Scala S, Milani R, Migliavacca M, Rovelli A, Bernardo ME, Ciceri F, Aiuti A, Biasco L.

Cytometry A. 2017 Oct;91(10):952-965. doi: 10.1002/cyto.a.23148. Epub 2017 Jun 13.

36.

A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors.

Santagata S, Portella L, Napolitano M, Greco A, D'Alterio C, Barone MV, Luciano A, Gramanzini M, Auletta L, Arra C, Zannetti A, Scala S.

Sci Rep. 2017 May 31;7(1):2554. doi: 10.1038/s41598-017-02818-6.

37.

Severe and rapidly-progressive Lafora disease associated with NHLRC1 mutation: a case report.

Casciato S, Gambardella S, Mascia A, Quarato PP, D'Aniello A, Ackurina Y, Albano V, Fornai F, Scala S, Di Gennaro G.

Int J Neurosci. 2017 Dec;127(12):1150-1153. doi: 10.1080/00207454.2017.1337012. Epub 2017 Jun 12.

PMID:
28556688
38.

Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach.

Gentilini D, Scala S, Gaudenzi G, Garagnani P, Capri M, Cescon M, Grazi GL, Bacalini MG, Pisoni S, Dicitore A, Circelli L, Santagata S, Izzo F, Di Blasio AM, Persani L, Franceschi C, Vitale G.

Oncotarget. 2017 Jun 27;8(26):41890-41902. doi: 10.18632/oncotarget.17462.

39.

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.

Botti G, Fratangelo F, Cerrone M, Liguori G, Cantile M, Anniciello AM, Scala S, D'Alterio C, Trimarco C, Ianaro A, Cirino G, Caracò C, Colombino M, Palmieri G, Pepe S, Ascierto PA, Sabbatino F, Scognamiglio G.

J Transl Med. 2017 Feb 23;15(1):46. doi: 10.1186/s12967-017-1150-7.

40.

CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients.

D'Alterio C, Nasti G, Polimeno M, Ottaiano A, Conson M, Circelli L, Botti G, Scognamiglio G, Santagata S, De Divitiis C, Nappi A, Napolitano M, Tatangelo F, Pacelli R, Izzo F, Vuttariello E, Botti G, Scala S.

Oncoimmunology. 2016 Nov 29;5(12):e1254313. doi: 10.1080/2162402X.2016.1254313. eCollection 2016.

41.

Tumour biomarkers: homeostasis as a novel prognostic indicator.

Falco M, Palma G, Rea D, De Biase D, Scala S, D'Aiuto M, Facchini G, Perdonà S, Barbieri A, Arra C.

Open Biol. 2016 Dec;6(12). pii: 160254. Review.

42.

Auditory Vigilance and Working Memory in Youth at Familial Risk for Schizophrenia or Affective Psychosis in the Harvard Adolescent Family High Risk Study.

Seidman LJ, Pousada-Casal A, Scala S, Meyer EC, Stone WS, Thermenos HW, Molokotos E, Agnew-Blais J, Tsuang MT, Faraone SV.

J Int Neuropsychol Soc. 2016 Nov;22(10):1026-1037.

PMID:
27903327
43.

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.

Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti AI, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, Perri F, Budillon A.

BMC Cancer. 2016 Nov 25;16(1):918.

44.

CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial.

Apetauerova D, Scala SA, Hamill RW, Simon DK, Pathak S, Ruthazer R, Standaert DG, Yacoubian TA.

Neurol Neuroimmunol Neuroinflamm. 2016 Aug 2;3(5):e266. doi: 10.1212/NXI.0000000000000266. eCollection 2016 Oct.

45.

Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.

Di Maro S, Trotta AM, Brancaccio D, Di Leva FS, La Pietra V, Ieranò C, Napolitano M, Portella L, D'Alterio C, Siciliano RA, Sementa D, Tomassi S, Carotenuto A, Novellino E, Scala S, Marinelli L.

J Med Chem. 2016 Sep 22;59(18):8369-80. doi: 10.1021/acs.jmedchem.6b00695. Epub 2016 Sep 9.

PMID:
27571038
46.

Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?

Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, Buonaguro L, Ciliberto G, Brauchli P, Pignata S.

Cancer Treat Rev. 2016 Jul;48:61-8. doi: 10.1016/j.ctrv.2016.06.008. Epub 2016 Jun 18. Review.

PMID:
27362548
47.

In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases.

Biasco L, Pellin D, Scala S, Dionisio F, Basso-Ricci L, Leonardelli L, Scaramuzza S, Baricordi C, Ferrua F, Cicalese MP, Giannelli S, Neduva V, Dow DJ, Schmidt M, Von Kalle C, Roncarolo MG, Ciceri F, Vicard P, Wit E, Di Serio C, Naldini L, Aiuti A.

Cell Stem Cell. 2016 Jul 7;19(1):107-19. doi: 10.1016/j.stem.2016.04.016. Epub 2016 May 26.

48.

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.

Scognamiglio G, De Chiara A, Di Bonito M, Tatangelo F, Losito NS, Anniciello A, De Cecio R, D'Alterio C, Scala S, Cantile M, Botti G.

Int J Mol Sci. 2016 May 21;17(5). pii: E790. doi: 10.3390/ijms17050790.

49.

A New Splicing Mutation in the L1CAM Gene Responsible for X-Linked Hydrocephalus (HSAS).

Ferese R, Zampatti S, Griguoli AM, Fornai F, Giardina E, Barrano G, Albano V, Campopiano R, Scala S, Novelli G, Gambardella S.

J Mol Neurosci. 2016 Jul;59(3):376-81. doi: 10.1007/s12031-016-0754-3. Epub 2016 May 20.

PMID:
27207492
50.

Current Approaches and Future Perspectives for In Vivo Clonal Tracking of Hematopoietic Cells.

Scala S, Leonardelli L, Biasco L.

Curr Gene Ther. 2016;16(3):184-93. Review.

PMID:
27121108

Supplemental Content

Support Center